SCHEMBL23934110

SCHEMBL23934110

COc1ccc(CCC(C)Cc2ccc(CCC(C)C)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.53
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
AOC3 Q16853 2/20 0.51
TAAR1 Q96RJ0 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPK1 P28482 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
LDHA P00338 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
ALOX15 P16050 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL879606 0.89 HTT (0.62) SLC6A4HTTSMN1; SMN2AOC3TAAR1
SCHEMBL20172543 0.80 SLC6A4 (0.58) SLC6A4HTTSMN1; SMN2MEN1KMT2A
SCHEMBL12339254 0.80 HTT (0.57) SLC6A4HTTSMN1; SMN2AOC3TAAR1
SCHEMBL13166017 0.80 SLC6A4 (0.58) SLC6A4HTTSMN1; SMN2MEN1KMT2A
SCHEMBL13166015 0.80 SLC6A4 (0.58) SLC6A4HTTSMN1; SMN2MEN1KMT2A
SCHEMBL21323940 0.80 SLC6A4 (0.62) SLC6A4AOC3TAAR1L3MBTL1POLB
SCHEMBL18557398 0.79 HTT (0.56) SLC6A4HTTSMN1; SMN2AOC3TAAR1
SCHEMBL28347286 0.79 ALDH1A1 (0.60) HTTSMN1; SMN2MAPK1L3MBTL1POLB
SCHEMBL28347287 0.79 ALDH1A1 (0.60) HTTSMN1; SMN2MAPK1L3MBTL1POLB
SCHEMBL4865413 0.79 SLC6A4 (0.61) SLC6A4HTTSMN1; SMN2TAAR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210369867-A1 LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY NUTCRACKER THERAPEUTICS, INC. (US) 2021-12-02 US disclosed
US-20210324002-A1 TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY NUTCRACKER THERAPEUTICS, INC. (US) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210369867-A1 LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY PHOSPHO1, PLIN3, CETP SLC6A4 2707/4885HTT 1115/4885SMN1; SMN2 2989/4885
US-20210324002-A1 TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY LNPEP, SLC7A1, APLNR SLC6A4 1957/4885HTT 1069/4885SMN1; SMN2 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.